There is a continuing debate about the proportion of cancer patients that benefit from
precision oncology, attributable in part to conflicting views as to which molecular alterations …

Advances in molecular diagnostics have enabled the identification of targetable driver
pathogenic variants, forming the basis of precision oncology care. However, the adoption of …

Ethnic or racial differences in breast cancer (BC) survival outcomes have been reported, but
current data are largely restricted to comparisons between African Americans and non …

Although the incidence of endometrial carcinoma (EC) is similar in Black and White women,
racial disparities are stark, with the highest mortality rates observed among Black patients …

Cancer genomes from patients with African (AFR) ancestry have been poorly studied in
clinical research. We leverage two large genomic cohorts to investigate the relationship …

This article presents a review of recent major advances in precision oncology and the future
implications of these advances, specifying the iterative progress achieved from the end of …

Background Racial disparities in outcomes exist in endometrial cancer (EC). The
contribution of ancestry‐based variations in germline pathogenic variants (gPVs) is …

Tumor type guides clinical treatment decisions in cancer, but histology-based diagnosis
remains challenging. Genomic alterations are highly diagnostic of tumor type, and tumor …

Background Telomerase reverse transcriptase (TERT) gene promoter mutations have been
explored, as biomarkers of improved survival for patients with cancer receiving immune …

Using 48,627 samples from the Center for Cancer Genomics and Advanced Therapeutics (C-
CAT), we present a pan-cancer landscape of driver alterations and their clinical actionability …